This short article describes how Organovo is using a novel technology called bioprinting to produce liver and kidney tissues that could help reshape the way drugs are tested and organs are transplanted in our days. It also discusses the challenges and potential effects on society.
Organovo, kicked off use of 3D printed liver tissue in big pharma research and drug development. Can it catapult the industry to shorten drug development cycle time and print entire liver organs in the next 15 yrs?
Additive manufacturing – also known as 3D-printing – has gained significant traction in commercial industries. In the medical community, there is promise of applying additive manufacturing techniques to tissue engineering, with the hope of developing replacement organs, ending the current unsatisfiable demand for transplants.
Organovo is a company developing 3D-bioprinted products for pharmacologic research and development, with a longer-term goal of developing printed tissue platforms. But is there truly a need for 3D-bioprinted products in this space? And is the idea of a 3D-printed organ merely a pipe dream?
When machine components deteriorate beyond repair, they are replaced. Can 3D bioprinting enable the human body to be maintained like a machine?